Shares of Indoco Remedies have gained as the company announced that it will be resuming the operations of its manufacturing plants in Goa.

These plants primarily manufacture opthalmic products in Goa Unit II, which are to be sold in the US market.

Currently, the company supplies the products to Canadian Markers.

The company has sent its final response on remedial measures at its Goa Plant to the USFDA, and is likely to seek audit from the regulator soon.

Indoco Remedies Ltd is currently trading at Rs 268.1, up by Rs 8.05 or 3.1% from its previous closing of Rs 260.05 on the BSE. The scrip opened at Rs 264.75 and has touched a high and low of Rs 270 and Rs 264.5 respectively.